Galaxa Pharma a/s: Financial statements 2023
CVR: 41183144
Source: annual report 2023, Danish Business Authority
01/10/2022 – 30/09/2023
Galaxa Pharma a/s (CVR 41183144) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,971,399 and a net result of DKK -1,742,863 compared with DKK -2,045,843 the year before. Equity in the 2023 report amounted to DKK 571,521. The solvency ratio was 22.1%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,971,399
- Profit/Loss
- DKK -1,742,863
- Equity
- DKK 571,521
- Total Assets
- DKK 2,583,984
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -2M | -1.7M | 572K | 1 |
| 2022 | - | -846K | -2M | 814K | 2 |
| 2021 | 666K | -6K | -134K | 360K | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 20, 2023, Karsten Adelmark has left the board of directors of Galaxa Pharma a/s.
As of June 30, 2023, Karsten Adelmark has joined the board of directors of Galaxa Pharma a/s.
As of June 30, 2023, Alexandre Fevre has left the board of directors of Galaxa Pharma a/s.
Galaxa Pharma a/s has published its annual report for 2022. Gross profit came to DKK -845,553, and the net result was DKK -2,045,843.
As of February 14, 2023, Stein Arve Løkstad has left the board of directors of Galaxa Pharma a/s.
About Galaxa Pharma a/s
Galaxa Pharma a/s is a Danish company of the type Aktieselskab based in København Ø, founded in 2020. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named CanNordic A/S. The management consists of Lone Henriksen. The board consists of Gitte Henriksen, Jens Jørgen Hagelskjær and Lone Henriksen. The company is owned by CS MEDICA a/s. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK -398,874 and a net result of DKK -461,281 compared with DKK -819,815 the year before. Equity in the 2025 report amounted to DKK -209,574.